跳至主要内容
临床试验/NCT00156143
NCT00156143已完成3 期

GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.

Pfizer0 个研究点目标入组 90 人开始时间: 2002年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
90
主要终点
Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.

研究概览

简要总结

To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
15 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Males or females : Chronological age > or = 15 years and < or = 20 years for females
  • •Chronological age > or = 17 years and < or = 20 years for males
  • •GHD of childhood onset treated for at least 2 years
  • •Last GH injection at least 12 months before baseline visit

排除标准

  • •Turner's syndrome
  • •Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN

结局指标

主要结局

Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry

相似试验